- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03279237
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer.
The interventions involved in this study are:
-FOLFIRINOX which is made up of 4 different drugs:
- 5-Fluorouracil (5-FU)
- Oxaliplatin
- Irinotecan
- Leucovorin
- Paclitaxel
- Carboplatin
- Proton Beam Radiation Therapy
Study Overview
Status
Conditions
Detailed Description
This research study is a Pilot Study, which is the first time investigators are examining this study intervention.
In this research study, the investigators are studying the combination of FOLFIRINOX followed by radiation with paclitaxel and carboplatin before surgery. The investigators believe that this intervention may help decrease the growth and spread of the cancer cells.
FOLFIRINOX has shown to be very effective in patients whom disease has spread. The investigators are evaluating this regimen to see if there is an increase in curability when the cancer has not spread.
The FDA (the U.S. Food and Drug Administration) has approved FOLFIRINOX as a treatment option for this disease.
The FDA has not approved Paclitaxel or Carboplatin for this specific disease but they have both been approved for other uses.
FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink the tumor before surgery.
Carboplatin may stop the cancer cells from growing and paclitaxel may stop the cancer cells from growing and spreading
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed T 3/4 or N+ (> 1 cm in size or FDG avid) gastric or gastroesophageal (GE) junction cancer. Diagnosis must be confirmed by the Mass General Hospital pathology department.
- Age 18 years or older. There will be no upper age restriction.
- ECOG performance status ≤ 1
- Life expectancy of greater than 3 months
Participants must have adequate organ and marrow function as defined below:
- absolute neutrophil count ≥ 1,500 cells/mm3
- platelets ≥ 75,000 cells/mm3
- total bilirubin ≤ 1.5 x upper limit of normal, or, for patients who have
- undergone biliary stenting, total bilirubin of ≤ 2 or two down trending values.
- AST(SGOT) ≤ 2.5 × upper limit of normal
- ALT (SGPT) ≤ 2.5 x upper limit of normal
- creatinine ≤ 1.5 mg/dL, or
- creatinine clearance ≥ 30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
- The effects of both radiation therapy and the chemotherapy agents used in this trial are known to be teratogenic. Therefore, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation plus 30 days from the last date of study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Evidence of metastatic disease as determined by chest CT scan, abdomen/pelvis CT scan (or MRI with gadolinium and/or manganese) within six weeks of study entry. Distant nodal disease is allowed if it is in the radiation port.
- Any prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the participant's gastric or GE junction cancer.
- Receipt of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Treatment of other invasive carcinomas within the last five years with greater than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.
- Receipt of any other investigational agents within 4 weeks preceding the start of study treatment.
- Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), such as significant cardiac or pulmonary morbidity (e.g. congestive heart failure, symptomatic coronary artery disease and/or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months, or ongoing infection as manifested by fever.
- History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or drug intake.
- Pregnant women are excluded from this study because radiation therapy and the chemotherapy agents to be used have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued while the mother is receiving protocol therapy.
- Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery.
- No concurrent administration of cimetidine (as it can decrease the clearance of 5-FU). Another H2-blocker or proton pump inhibitor may be substituted before study entry.
- Known, existing uncontrolled coagulopathy.
- Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and at least six months earlier). Prior topical fluoropyrimidine use is allowed.
- Known hypersensitivity to 5-fluorouracil or known DPD deficiency.
- History of allergic reaction(s) attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFIRINOX + pre-operative radiation
|
May help shrink tumor before surgery.
Other Names:
May help shrink tumor before surgery.
Other Names:
May help shrink tumor before surgery.
May help shrink tumor before surgery.
Other Names:
Paclitaxel may stop cancer cells from growing and spreading.
Other Names:
May help shrink tumor.
Carboplatin may stop cancer cells from growing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Completion Rate of Chemotherapy in Combination With Chemoradiation
Time Frame: 21 weeks
|
The number of participants that complete the assigned study intervention.
|
21 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Time Frame: From the start of treatment until 30 days after the end of treatment (up to approximately 25 weeks)
|
The number of participants that experienced at least one treatment related adverse event as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.0).
|
From the start of treatment until 30 days after the end of treatment (up to approximately 25 weeks)
|
Clinical Response Rate
Time Frame: After 4 and 8 cycles of FOLFIRINOX (8 and 16 weeks); and 3-4 weeks after chemo radiation (24-25 weeks)
|
The number of participants that achieved a clinical response following treatment. Clinical response is defined as achieving a best overall response of a complete response (CR) or a partial response (PR).
|
After 4 and 8 cycles of FOLFIRINOX (8 and 16 weeks); and 3-4 weeks after chemo radiation (24-25 weeks)
|
Pathologic Complete Response Rate
Time Frame: 29 Weeks
|
The number of participants that achieve a pathologic complete response at surgery following FOLFIRINOX and chemoradiation.
All patients will undergo a full pathological review of their surgical specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th edition.
Initial gross evaluation and identification of resection margins will be performed jointly by the surgeon and the pathologist.
Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen.
|
29 Weeks
|
Progression Free Survival
Time Frame: 5 Years
|
Progression-free survival (PFS) is defined as the time from the date of first dosing to the first documentation of radiographic disease progression per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) or death due to any cause, whichever occurs first. Subjects who are alive with no documented progressive disease by the data cutoff date for PFS analysis will be censored at the date of their last evaluable disease assessment. Progressive Disease (PD) is defined as having at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). |
5 Years
|
Overall Survival
Time Frame: 5 Years
|
The number of participants alive five years after the start of treatment.
Overall survival (OS) is measured as the time from the date of first dosing until death due to any cause.
If there is no death reported for a subject by the data cut-off date for overall survival analysis, OS will be censored at the last known alive date.
|
5 Years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Carboplatin
- Paclitaxel
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Irinotecan
Other Study ID Numbers
- 17-311
- U19CA021239-37 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GastroEsophageal Cancer
-
Jesper Frank Christensen, PhDLundbeck Foundation; Region Capital Denmark; Beckett FoundationActive, not recruiting
-
H. Lee Moffitt Cancer Center and Research InstituteRecruitingGastroEsophageal CancerUnited States
-
Rigshospitalet, DenmarkDanish Cancer SocietyCompletedGastroesophageal-junction CancerDenmark
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdCompletedGastric/Gastroesophageal Junction CancerChina
-
M.D. Anderson Cancer CenterRecruitingGastrostomy | GastroEsophageal Cancer | GastricUnited States, Japan, Korea, Democratic People's Republic of
-
AmgenCompletedGastric or Gastroesophageal CancerJapan
-
Centre Leon BerardRecruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction CancerChina
-
Memorial Sloan Kettering Cancer CenterTerminatedGastric Cancer | Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Junction Cancer | Gastric Tumor | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer | Esophageal Tumor | Esophagogastric Tumors | Gastroesophageal Junction TumorUnited States
-
Charite University, Berlin, GermanyNot yet recruitingGastric and Gastroesophageal Junction CancerGermany
Clinical Trials on Irinotecan
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.CompletedMetastatic Colorectal Cancer
-
ShengFa SuUnknownSmall-cell Lung CancerChina
-
Nelson YeeIpsenActive, not recruitingLocally Advanced Pancreatic Carcinoma(LAPC)United States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedGlioma | Astrocytoma | OligodendrogliomaUnited States
-
Centre Oscar LambretSFCECompleted
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Japan Clinical Cancer Research OrganizationTaiho Pharmaceutical Co., Ltd.Completed
-
Boston Scientific CorporationBiocompatibles UK LtdCompletedMetastatic Colorectal CancerUnited Kingdom, Austria, France
-
Dong-A University HospitalPusan National University Yangsan HospitalCompletedGastric CancerKorea, Republic of